Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma

BACKGROUND: The PD-L1 antibody is an immune checkpoint inhibitor (ICI) attracting attention. The third-generation anticancer drug has been proven to be very effective due to fewer side effects and higher tumor-specific reactions than conventional anticancer drugs. However, as tumors produce addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Guen Tae, Kim, Eun Young, Shin, Su-Hyun, Lee, Hyowon, Lee, Se Hee, Sohn, Ki-Young, Kim, Jae Wha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251917/
https://www.ncbi.nlm.nih.gov/pubmed/35787261
http://dx.doi.org/10.1186/s12885-022-09815-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251917/
https://www.ncbi.nlm.nih.gov/pubmed/35787261
http://dx.doi.org/10.1186/s12885-022-09815-7

Ejemplares similares